Memantine

Memantine. It is a medication primarily used to treat moderate to severe Alzheimer's disease, acting as a low-to-moderate affinity, non-competitive NMDA receptor antagonist. Approved for medical use in the United States in 2003 and in the European Union earlier, it is often prescribed when a patient can no longer tolerate or has not responded adequately to acetylcholinesterase inhibitors like donepezil. The drug is also investigated for other neurological conditions, including vascular dementia and certain forms of autism spectrum disorder.

Medical uses

The primary approved indication is for the treatment of moderate to severe Alzheimer's disease, where it is used to slow the progression of cognitive decline. It may be used alone or in combination with an acetylcholinesterase inhibitor such as rivastigmine or galantamine. Some clinical guidelines, including those from the National Institute for Health and Care Excellence, support its use in these stages of the disease. Off-label, it has been studied for conditions like obsessive-compulsive disorder, attention deficit hyperactivity disorder, and certain types of neuropathic pain, though evidence for these uses is less robust.

Adverse effects

Common adverse effects are generally mild to moderate and may include dizziness, headache, constipation, and confusion. Less frequently, patients may experience hypertension, dyspnea, or hallucinations. Serious side effects are rare but can include heart failure and seizures. The side effect profile is often considered more favorable than that of typical antipsychotics, which are sometimes used for behavioral and psychological symptoms of dementia. Caution is advised in patients with severe renal impairment, as excretion is primarily renal.

Pharmacology

Memantine exerts its therapeutic effect through antagonism of the NMDA receptor, a type of ionotropic glutamate receptor central to learning and memory. It binds preferentially to the receptor's phencyclidine site within the ion channel, blocking the path of calcium ions only during prolonged activation by glutamate, as seen in excitotoxicity. This mechanism is described as an uncompetitive, voltage-dependent antagonism, which allows for normal physiological neurotransmission to occur. Its pharmacokinetics show high oral bioavailability and minimal metabolism by the liver, with a very long elimination half-life.

History

The compound was first synthesized and patented in 1968 by the German company Merz & Co. as a potential antidiabetic drug. Its neuroprotective properties were later discovered, leading to research for neurological applications. It received approval in the European Union for the treatment of Alzheimer's disease in 2002. The U.S. Food and Drug Administration granted approval in 2003 following clinical trials submitted by Forest Laboratories. The development of memantine represented a shift from cholinergic strategies to targeting the glutamatergic system in dementia therapeutics.

Society and culture

Memantine is marketed under various brand names worldwide, including Namenda in the United States and Ebixa in many European countries. Its introduction sparked significant discussion within organizations like the Alzheimer's Association regarding cost-effectiveness and the modest nature of its clinical benefits. The drug's patent expiration led to the introduction of generic versions and a once-daily extended-release formulation. It has been featured in treatment guidelines by major bodies such as the American Psychiatric Association and remains a subject of ongoing clinical research by institutions like the National Institutes of Health.

Category:Dementia medications Category:NMDA receptor antagonists Category:Merz & Co.